Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Outcomes after carotid endarterectomy among elderly dual Medicare-Medicaid–eligible patients
Leifheit, Erica C , Wang, Yun , Howard, George , Howard, Virginia J. , Goldstein, Larry B. , Brott, Thomas G. , Lichtman, Judith H. , Howard, Virginia J , Howard, George

Mayo Clinic

Neurology | September 29, 2018 | Volume: 91 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000006380 | PMID 30266891 Get It

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements
Luchtel, Rebecca A. , Dasari, Surendra , Pedersen, Martin Bjerregård , Hu, Guangzhen , Sidhu, Jagmohan S. , Katoh, Ryohei, Kip, N. Sertac, Cunningham, Julie M. , Sun, Zhifu , Baheti, Saurabh , Porcher, Julie C., Said, Jonathan , Jiang, Liuyan , Hamilton‐Dutoit, Stephen , Møller, Michael , Nørgaard, Peter , Link, Brian K. , d’Amore, Francesco, Ansell, Stephen M. , Hamilton-Dutoit, Stephen Jacques , Møller, Michael Boe , Feldman, Andrew L , Sun, Zhifu , Link, Brian K , Oishi, Naoki , Rech, Karen L. , Ketterling, Rhett P. , Wang, Xueju , Doǧan, Ahmet , Bennani, N. Nora , Chng, Wee Joo , Huang, Gaofeng , Facchetti, Fabio , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | September 27, 2018 | Volume: 132 | Issue: 13 | Pages: 1386-1398

10.1182/blood-2018-03-838524 | PMID 30093402 Get It

Key PointsDUSP22-rearranged ALCLs belong to a distinct subset of ALCLs lacking activated STAT3. DUSP22-rearranged ALCLs have a unique molecular signature characterized by DNA hypomethylation and an immunogenic phenotype.
Use of online symptom checkers to delineate the ever‐elusive GERD versus non‐GERD cough
Berry, Andrew C. , Berry, Nicholas A. , Wang, Bin , Mulekar, Madhuri S. , Melvin, Anne, Battiola, Richard J., Bulacan, Frederick K., Berry, Bruce B.

Mayo Clinic

The Clinical Respiratory Journal | September 27, 2018 | Volume: 12 | Issue: 12 | Pages: 2683-2685

10.1111/crj.12966 | PMID 30260573 Get It

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica, Alphonse E. , Groopman, John D. , Selaru, Florin M. , Wang, Xin Wei , Zhu, Andrew X. , Wei Wang, Xin , Groopman, John D , Gores, Gregory J. , Strazzabosco, Mario

Mayo Clinic

Hepatology | September 25, 2018 | Volume: 69 | Issue: 4 | Pages: 1803-1815

10.1002/hep.30289 | PMID 30251463 Get It

Intrahepatic cholangiocarcinoma (iCCA) has over the last 10‐20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide. The significant increase in mortality rates from this primary hepatobiliary cancer, particularly over the past decade, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates to seek greater mechanistic insights and more effective biomarker‐driven targeted approaches for managing and/or preventing this challenging liver cancer. In addition to discussing challenges posed by this aggressive cancer, this review will emphasize recent epidemiological, basic, and translational research findings for iCCA. In particular, we will highlight emerging demographic changes and evolving risk factors, the critical role of the tumor microenvironment, extracellular vesicle biomarkers and therapeutics, intertumoral and intratumoral heterogeneity, and current and emerging targeted therapies regarding iCCA. Specifically, recent evidence linking non–bile duct medical conditions, such as nonalcoholic fatty liver disease and nonspecific cirrhosis, to intrahepatic cholangiocarcinogenesis together with geographic and ethnic variation will be assessed. Recent developments concerning the roles played by transforming growth factor‐β and platelet‐derived growth factor D in driving the recruitment and expansion of cancer‐associated myofibroblasts within cholangiocarcinoma (CCA) stroma as well as their therapeutic implications will also be discussed. In addition, the potential significance of extracellular vesicles as bile and serum biomarkers and therapeutic delivery systems for iCCA will be described. An integrated systems approach to classifying heterogeneous iCCA subtypes will be further highlighted, and recent clinical trials and emerging targeted therapies will be reviewed, along with recommendations for future translational research opportunities. Established international CCA networks are now facilitating collaborations aimed at advancing iCCA translational and clinical research.
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
Ljubenkov, Peter A. , Staffaroni, Adam M. , Allen, Isabel Elaine , Heuer, Hilary W. , Karydas, Anna, Kornak, John , Grinberg, Lea T. , Fagan, Anne M. , Jerome, Gina, Kramer, Joel H. , Miller, Bruce L. , Boxer, Adam L. , Rosen, Howard J. , Boeve, Brad F, Miller, Bruce L , Grinberg, Lea , Rojas, Julio C. , Wang, Ping , Cobigo, Yann , Seeley, William W. , Spina, Salvatore , Knopman, David S. , Boeve, Bradley F. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Clinical and Translational Neurology | September 21, 2018 | Volume: 5 | Issue: 10 | Pages: 1250-1263

10.1002/acn3.643 | PMID 30349860 Get It

AbstractObjectiveThe prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau181, and amyloid beta1‐42was examined in frontotemporal dementia subtypes.MethodsWe compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits.ResultsNeurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau181predicted faster clinical progression whereas lower amyloid beta1‐42predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau181were of greater predictive value in patients with tau pathology as compared toTDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia.InterpretationHigh cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau181, and amyloid beta1‐42also predict some measures of disease aggressiveness in frontotemporal dementia.
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis
Menghrajani, Kamal , Boonstra, Philip S. , Mercer, Jessica, Perkins, Cecelia , Gowin, Krisstina , Weber, Alissa A., Wang, Lixia , Talpaz, Moshe , Gowin, Krisstina L, Mesa, Ruben, Talpaz, Moshe , Mesa, Ruben A. , Gotlib, Jason , Singer, Jack W.

Mayo Clinic

Leukemia & Lymphoma | September 20, 2018 | Volume: 60 | Issue: 4 | Pages: 1036-1042

10.1080/10428194.2018.1509315 | PMID 30234400 Get It

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Roy, Debarshi , Bhattacharya, Sayantani Sarkar , Jin, Ling, Jung, Deok‐Beom , Kalogera, Eleftheria , Staub, Julie , Wang, Yaxian , X, Wen, Khurana, Ashwani, Chien, Jeremy , Telang, Sucheta , Chesney, Jason , Tapolsky, Gilles , Petras, Dzeja, Shridhar, Viji , Mondal, Susmita, Roy, Debarshi , Sarkar Bhattacharya, Sayantani, Jung, Deokbeom, Xuyang, Wen, Chien, Jeremey , Sarkar Bhattacharya, Sayantani , Mondal, Susmita, Zhang, Song, Xuyang, Wen, Petras, Dzeja

Mayo Clinic

International Journal of Cancer | September 18, 2018 | Volume: 144 | Issue: 1 | Pages: 178-189

10.1002/ijc.31868 | PMID 30226266 Get It

Metabolic alterations are increasingly recognized as important novel anti‐cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158‐induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co‐immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158‐mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX‐resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.
Measurement of Low‐Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry
Lowenstern, Angela , Li, Shuang , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Lee, L. Veronica, Louie, Michael J. , Wang, Tracy Y., Návar, Ann Marie , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 16, 2018 | Volume: 7 | Issue: 18 | Pages: No page available

10.1161/jaha.118.009251 | PMID 30371214 Get It

Background The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults recommended testing low‐density lipoprotein cholesterol ( LDL ‐C) to identify untreated patients with LDL ‐C ≥190 mg/dL, assess lipid‐lowering therapy adherence, and consider nonstatin therapy. We sought to determine whether clinician lipid testing practices were consistent with these guidelines. Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry enrolled primary and secondary prevention patients from 140 US cardiology, endocrinology, and primary care offices in 2015 and captured demographic data, lipid treatment history, and the highest LDL ‐C level in the past 2 years. Core laboratory lipid levels were drawn at enrollment. Among 7627 patients, 2787 (36.5%) had no LDL ‐C levels measured in the 2 years before enrollment. Patients without chart‐documented LDL ‐C levels were more often women, nonwhite, uninsured, and non–college graduates (all P <0.01). Patients without prior lipid testing were less likely to receive statin treatment (72.6% versus 76.0%; P =0.0034), a high‐intensity statin (21.5% versus 24.3%; P =0.016), nonstatin lipid‐lowering therapy (24.8% versus 27.3%; P =0.037), and had higher core laboratory LDL ‐C levels at enrollment (median 97 versus 92 mg/dL; P <0.0001) than patients with prior LDL ‐C testing. Of 166 individuals with core laboratory LDL ‐C levels ≥190 mg/dL, 36.1% had no LDL ‐C measurement in the prior 2 years, and 57.2% were not on a statin at the time of enrollment. Conclusions In routine clinical practice, LDL ‐C testing is associated with higher‐intensity lipid‐lowering treatment and lower achieved LDL ‐C levels.
PS01.045: ENDOSCOPIC NEGATIVE INTRACAVITARY PRESSURE (ENDO-NIP) TO MANAGE ESOPHAGEAL LEAK AND MEDIASTINAL ABSCESS COMPLICATED BY STROKE TREATED WITH TPA
Singh, Prabh G. , Bhangoo, Harangad S. , Meyer, Alyssa J. , Rizvi, Zaheer H., Buttar, Navtej , Wang, Kenneth , Singh, Prabh G

Mayo Clinic

Diseases of the Esophagus | September 16, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 62-63

10.1093/dote/doy089.ps01.045 Get It

Abstract Background Post-surgical complications such as leaks are the source of considerable morbidity and mortality. Success of conservative interventions is highly variable. Recurrence after surgical repair is also not uncommon. Our aim was to develop novel endoscopic strategies to maximize negative intracavitary pressure to manage leaks in cases where conventional management either failed or were not feasible. Methods We have used transluminal locking loop drains with low intermittent suction in the management of non-healing leaks in various areas. An example presented here illustrates this concept where a 68-year-old male patient underwent paraesophageal hernia repair with Nissen fundoplication. Patient presented 3 weeks later with fistula leading to a 13 cm meditational abscess. Patient developed right hemiparesis requiring tissue plasminogen activator (tPA). Post-tPA patient developed hemoptysis and hematemesis requiring emergency intubation. The defect in the esophagus was 6–8 mm. Endoscopic repair with stitching or clipping would have left a large undrained cavity with a potential to expand. Endoscopic repair with transcutaneous drain placement was challenging due to recent tPA and a difficult location. Moreover there was potential to develop esophago- pleural- broncho- cutaneous fistula. Endoscopic vacuum therapy was felt to be a suboptimal choice. Patient was high-risk surgical candidate as it would have required radical surgery in the setting of tPA.Upper endoscopy was performed and the cavity was debrided. No direct communication with bronchopulmonary tree noted. A transnasal guidewire assisted 16 Fr, 60 cm locking loop drain was placed and connected to low intermittent suction that was switched to bulb based suction. Results The output from naso-cavity drain decreased nearly 100 cc per day in the first 5 days and the size reduced by 30, 50 and 80% by day 5, 9 and 12 respectively. Near complete elimination of the cavity was observed on day 15. Esophagogram showed complete resolution of the leak and computerized tomography revealed no residual cavity Conclusion Developing transluminal endoscopic strategies to maximize negative intracavitary pressure helps expedite the healing of resistant postsurgical leaks. This technique avoids the need for frequent drain changes that remains a challenge for vacuum therapy. Disclosure All authors have declared no conflicts of interest.
FA02.07: BARRIER STRUCTURE AND FUNCTION OF THE NEO-SQUAMOUS EPITHELIUM FOLLOWING SUCCESSFUL BARRETT’S ENDOTHERAPY IS IMPAIRED
Ravindran, Adharsh, Blevins, Christopher H. , Johnson, Michele L., Lansing, Ramona, Katzka, David A. , Iyer, P. K. R., Wang, Kenneth , Iyer, Prasad

Mayo Clinic

Diseases of the Esophagus | September 14, 2018 | Volume: 31 | Issue: Supplement_1 | Pages: 5-5

10.1093/dote/doy089.fa02.07 Get It

Abstract Background The neo-squamous epithelium that replaces columnar epithelium after successful endoscopic ablation of Barrett's esophagus (BE) has not been fully characterized in regard to its structural and functional integrity. Intercellular space is a surrogate marker for epithelial structural integrity and mucosal impedance (MI) is a surrogate for transepithelial resistance and thus epithelial functional integrity. Impairment of the structural and functional integrity may influence recurrence following successful ablation. We aimed to measure the esophageal epithelial intercellular space diameter and MI in the neo-squamous and normal squamous epithelium of patients who underwent successful radiofrequency ablation for dysplastic BE. Methods Forty patients with complete remission of intestinal metaplasia (CRIM) (defined as two negative surveillance endoscopies for intestinal metaplasia) were prospectively recruited. Patients were excluded if they had endoscopic evidence of esophagitis. MI measurements were taken at 1 cm above the GE junction and 2 cm above the prior BE segment (targeting uninvolved squamous epithelium), using a novel through the scope MI probe. Endoscopic biopsies were also taken at these corresponding sites to assess intercellular space diameter using transmission electron microscopy (TEM) using standard techniques. Results 80% of patients were male with a mean age of 69 years. Mean follow since achieving CRIM was 30 months. 39 patients underwent RFA for dysplasia. The mean intercellular space diameter was higher in the neo-squamous epithelium (1.01 μm) when compared to the untreated native squamous epithelium (0.96 μm) [Difference of 0.056 μm, 95% CI of -0.036 to 0.148, P = 0.228]. The mean MI was significantly lower in the neosquamous epithelium (4001.3 Ω) when compared to the untreated native epithelium (5168.1 Ω) [Difference of 1166.7 Ω, 95% CI 418.8 to 1914.6, P = 0.003]. Conclusion Neo-squamous epithelium that replaces BE epithelium following successful endoscopic therapy for BE appears to be functionally and likely structurally deficient with regards to acid reflux barrier function, when compared to native squamous esophageal epithelium. This impairment may be associated with recurrence following successful ablation. Disclosure All authors have declared no conflicts of interest.